Repligen Reports Fourth Quarter ........ "RG2833 for Friedreich’s Ataxia"

9th of June 2011

RG2833 for Friedreich’s Ataxia
We are currently developing histone deacetylase class 1 inhibitors for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. Friedreich's ataxia is caused by inadequate production of the protein frataxin which leads to degeneration of the nerves controlling muscle movements. Pending regulatory approval, we plan to initiate a Phase 1 study of RG2833 in Friedreich's ataxia patients in Europe by the end of the year. We are currently engaged in discussions with potential
pharmaceutical partners to evaluate whether partnering this program would increase the trajectory for global development and ultimately maximize the commercial potential of the asset.

Stem Cell Transplantation Offers 'Sea Of Opportunity' For Treating Debilitating Diseases

Medical News Today, Article Date: 09 Jun 2011

An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors ™ reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases. read more...

Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation

Medical News Today, Article Date: 09 Jun 2011

Edison Pharmaceuticals, Inc. announced the United States Food and Drug Administration has granted orphan drug designation to EPI-743 for treatment of inherited mitochondrial respiratory chain diseases. read more

Edison Pharmaceuticals ofrecerá un acceso ampliado al EPI-743 para la enfermedad mitocondrial

MOUNTAIN VIEW, California, 8 de junio de 2011 /PRNewswire/

La FDA autorizó un Programa de Acceso Ampliado con el propósito de administrar el fármaco en fase de investigación EPI-743 a los pacientes graves diagnosticados con enfermedades mitocondriales heredadas de la cadena respiratoria. leer más...